In Contract Mining, which management calls its growth platform, the company started a multi-year dragline services contract on a U.S. Army Corps of Engineers project in Palm Beach County, Florida, in early 2026 and began operating a limestone quarry in Arizona under a contract …
Performance Materials sales were USD 154.1 million against USD 155.0 million, as North American automotiveDemandand higher non-auto filtration sales, driven by pricing, offset lower volumes in China and Europe. Pavement Technologies sales were USD 106.0 million against USD 139.9 million, a decline of 24% …
In the senior housing operating portfolio, Same Store Cash NOI growth was 13.6%, average occupancy was 86.7%, RevPOR rose 4.0% and Cash NOIMarginwas 24.3%. In the outpatient medicalFacilitysegment, Same Store Cash NOI decreased 0.3% and ending occupancy was 95.6%.
Total revenue rose 25% on higher combined time charter equivalent rates. The combined rate was USD 30,371 per day, up 26%, on 13,479 available days, which the company described as slightly more than in the third quarter of 2025. The dry bulk rate rose …
Third quarter acquisitions were completed or committed before the shift. The company invested USD 222 million in 76 properties at an initial cap rate of 7.3%, with a weighted averageLeaseterm above 19 years and a projected long-termYieldof 8.4% including contractual rent escalators. Over nine …
Net income was USD 26.54 million against USD 30.91 million. Income from operations was USD 27.09 million against USD 32.68 million. Adjusted EBITDA was USD 37.75 million, which the partnership described as USD 1.2 million lower than the prior-year quarter.
Management said its Enterprise segment continues to see underlyingDemandfor Pro AV managed switches, but that revenue is constrained byManufacturingoutput at a contract manufacturer bringing a new factory online. It said the constraint would persist into the first quarter of 2027, that Enterprise revenue would …
IBTROZI is approved in the United States for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer, and U.S. sales are the company's only source of product revenue. Net product revenue was USD 27.46 million for the quarter and USD 69.16 …
Sales of USD 691.5 million compare with USD 669.9 million in the third quarter of 2025, and the company stated sales growth of 3.2% and core sales growth of 2.7%.Gross Profitwas USD 400.6 million against USD 370.2 million. Cost of sales included the receipt …
Other, net was a gain of USD 38 million, against USD 4 million in the prior-year quarter, and the company said the REA India gain and higher Total Segment EBITDA were the main drivers of net income.Net Incomerose to USD 215 million from USD …